Baseline PSA levels reliably and independently predicts death from prostate cancer, with a baseline reading of 4 ng/mL or higher linked with greater mortality risk. In 4,568 men diagnosed with the disease over a recent 20-year period, those with baseline PSA levels of 4.0-9.9 ng/mL were three times more likely to die from prostate cancer than men with lower values, researchers Ping Tang, MD, and colleagues reported online in Cancer.
The mortality risk was 11 times higher when the baseline PSA value was greater than 10 ng/mL compared with values below 2.5 ng/mL. African-American men and men at advanced age at baseline PSA measurement had higher death rates from prostate cancer and all causes.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.